Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership
BMC Infectious Diseases, Volume 21, No. 1, Article 889, Year 2021
Notification
URL copied to clipboard!
Description
Background: Estimating population prevalence and incidence of prior SARS-CoV-2 infection is essential to formulate public health recommendations concerning the COVID-19 pandemic. However, interpreting estimates based on sero-surveillance requires an understanding of the duration of elevated antibodies following SARS-CoV-2 infection, especially in the large number of people with pauci-symptomatic or asymptomatic disease. Methods: We examined > 30,000 serology assays for SARS-CoV-2 specific IgG and IgM assays acquired longitudinally in 11,468 adults between April and November 2020 in the COVID-19 Community Research Partnership. Results: Among participants with serologic evidence for infection but few or no symptoms or clinical disease, roughly 50% sero-reverted in 30 days of their initial positive test. Sero-reversion occurred more quickly for IgM than IgG and for antibodies targeting nucleocapsid protein compared with spike proteins, but was not associated with age, sex, race/ethnicity, or healthcare worker status. Conclusions: The short duration of antibody response suggests that the true population prevalence of prior SARS-CoV-2 infection may be significantly higher than presumed based on earlier sero-surveillance studies. The impact of the large number of minimally symptomatic COVID-19 cases with only a brief antibody response on population immunity remains to be determined. © 2021, The Author(s).
Authors & Co-Authors
Wierzba, Thomas F.
United States, Winston Salem
Wake Forest University School of Medicine
Espeland, Mark Andrew
United States, Winston Salem
Wake Forest University School of Medicine
Bertoni, Alain G.
United States, Winston Salem
Wake Forest University School of Medicine
Mathews, Allison Christine
United States, Winston Salem
Wake Forest University School of Medicine
Runyon, Michael S.
United States, Charlotte
Atrium Health
Kotloff, Karen L.
United States, Baltimore
University of Maryland School of Medicine
Friedman-Klabanoff, De Anna J.
United States, Baltimore
University of Maryland School of Medicine
Weintraub, William S.
United States, Washington, D.c.
Washington Hospital Center
Correa, Adolfo
United States, Jackson
University of Mississippi Medical Center
Santacatterina, Michele
United States, Washington, D.c.
The George Washington University
Statistics
Citations: 30
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1186/s12879-021-06517-6
ISSN:
14712334
Research Areas
Covid
Health System And Policy
Study Design
Cross Sectional Study
Cohort Study